News & Updates

Relugolix: a new alternative to injectable ADTs for prostate cancer?

19 May 2020 by

The investigational, oral GnRH* receptor antagonist relugolix effectively and rapidly reduced and sustained testosterone to castration levels while exhibiting a favourable safety profile in men with prostate cancer (PCa), a phase II trial has shown.

Relugolix: a new alternative to injectable ADTs for prostate cancer?

19 May 2020

Blood test enables early detection of multiple cancers in women with no cancer history

18 May 2020 by

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Blood test enables early detection of multiple cancers in women with no cancer history

18 May 2020

Docetaxel with concurrent radiotherapy safe in most elderly oesophageal cancer patients

17 May 2020

Concurrent docetaxel with radiotherapy (DOC-RT) is generally safe in elderly patients with oesophageal cancer (EC), though caution should be advised in the very old and undernourished, a recent study has shown.

Docetaxel with concurrent radiotherapy safe in most elderly oesophageal cancer patients

17 May 2020

Infection prevalence increased before cancer diagnosis

15 May 2020 by

Individuals who develop cancer may have an elevated risk of certain infections in the years leading up to their diagnosis, a retrospective case-control study from Japan showed.

Infection prevalence increased before cancer diagnosis

15 May 2020

Original New Drug Application Approvals by US FDA (01 - 15 May 2020)

15 May 2020

New drug applications approved by US FDA as of 01 - 15 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 May 2020)

15 May 2020

Resection poses greater mortality risks in older PDAC patients

14 May 2020

Older patients with high comorbidity scores face greater mortality risks when undergoing pancreaticoduodenectomy, a recent study has shown.

Resection poses greater mortality risks in older PDAC patients

14 May 2020

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

14 May 2020 by

The PARP* inhibitor niraparib improves progression-free survival (PFS) and is well-tolerated in women with newly diagnosed advanced ovarian cancer (OCa) after a response to first-line (1L) platinum-based chemotherapy (CT), subgroup results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial have shown.

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

14 May 2020

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

14 May 2020 by

Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

14 May 2020

Younger breast cancer survivors have better cognition, exercise habits than older survivors

13 May 2020

Younger breast cancer survivors are more physically active and have better cognitive performance than their older counterparts, a new study has shown.

Younger breast cancer survivors have better cognition, exercise habits than older survivors

13 May 2020

Gemcitabine plus albumin-bound paclitaxel useful for treating advanced SQCLC

13 May 2020

The combination of gemcitabine plus albumin-bound paclitaxel (ABP) appears to be well tolerated and effective in the first-line treatment of patients with advanced squamous cell lung cancer (SQCLC), according to the results of a phase II study.

Gemcitabine plus albumin-bound paclitaxel useful for treating advanced SQCLC

13 May 2020

News & Updates

Filter by Specialty:

Specialty:

Relugolix: a new alternative to injectable ADTs for prostate cancer?

Relugolix: a new alternative to injectable ADTs for prostate cancer?

Blood test enables early detection of multiple cancers in women with no cancer history

Blood test enables early detection of multiple cancers in women with no cancer history

Docetaxel with concurrent radiotherapy safe in most elderly oesophageal cancer patients

Docetaxel with concurrent radiotherapy safe in most elderly oesophageal cancer patients

Infection prevalence increased before cancer diagnosis

Infection prevalence increased before cancer diagnosis

Original New Drug Application Approvals by US FDA (01 - 15 May 2020)

Original New Drug Application Approvals by US FDA (01 - 15 May 2020)

Resection poses greater mortality risks in older PDAC patients

Resection poses greater mortality risks in older PDAC patients

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

Younger breast cancer survivors have better cognition, exercise habits than older survivors

Younger breast cancer survivors have better cognition, exercise habits than older survivors

Gemcitabine plus albumin-bound paclitaxel useful for treating advanced SQCLC

Gemcitabine plus albumin-bound paclitaxel useful for treating advanced SQCLC